Trial reportBMC gastroenterology2026
Effect of a structured early rehabilitation program on long-term functional recovery, quality of life, and survival in patients with severe acute pancreatitis: a randomized controlled trial.
Trial report in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProlonged immobilization in patients with severe acute pancreatitis (SAP) leads to profound physical deconditioning, yet structured rehabilitation protocols remain underexplored in this population.
objectiveTo investigate the effects of a structured early rehabilitation nursing (ERN) program on short-term and long-term clinical outcomes, including length of stay, functional recovery, and survival, in patients with severe acute pancreatitis (SAP) admitted to the intensive care unit (ICU).
methodsThis single-center, prospective, randomized controlled trial was conducted from June 2019 to June 2024. A total of 400 eligible SAP patients admitted to the intensive care unit (ICU) were randomized (1:1) to either the ERN group (n = 200), receiving a protocolized, multidisciplinary rehabilitation program, or the control group (n = 200), receiving usual care. The primary outcome was hospital length of stay (LOS). Key secondary outcomes included ICU LOS, systemic inflammatory markers (CRP, IL-6), muscle strength (MRC sum score), activities of daily living (ADL), quality of life (WHOQOL-BREF), and 1-year all-cause mortality. Assessments were performed at baseline, discharge, and at 3, 6, and 12 months post-discharge.
resultsThe ERN group had significantly shorter hospital LOS (11.5 ± 2.5 vs. 14.8 ± 3.1 days, P < 0.001) and ICU LOS (7.2 ± 2.1 vs. 10.5 ± 2.8 days, P < 0.001). At day 7, the ERN group showed lower levels of CRP (48.5 ± 15.2 vs. 95.3 ± 25.4 mg/L, P < 0.001) and IL-6 (55.2 ± 18.3 vs. 110.6 ± 30.1 pg/mL, P < 0.001). At discharge, the ERN group demonstrated superior muscle strength (MRC score: 52.4 ± 4.9 vs. 46.1 ± 5.8, P < 0.001) and functional independence (ADL score: 75.8 ± 8.1 vs. 62.5 ± 9.3, P < 0.001). These functional and quality of life benefits were sustained through the 12-month follow-up. Kaplan-Meier analysis revealed a significantly higher 1-year survival rate in the ERN group (95.0% vs. 87.5%; log-rank P = 0.012). The incidence of ICU-acquired complications was also lower in the ERN group (5.5% vs. 26.0%, P < 0.001).
conclusionA structured, early rehabilitation nursing program for SAP patients effectively attenuates systemic inflammation, accelerates physical recovery, reduces length of stay, and improves long-term functional outcomes, quality of life, and 1-year survival. These findings support the integration of ERN as a standard of care in the management of critically ill SAP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.